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The Multidrug Resistance Protein, MRP1 (ABCC1) confers drug resistance and transports organic anions such as leukotriene C4 (LTC4)
and 17h-estradiol 17-(h-D-glucuronide) (E217hG). Previous studies showed that portions of the first membrane spanning domain (MSD1)
and the cytoplasmic loop (CL3) connecting it to MSD2 are important for MRP1 transport function. We have replaced 12 prolines in MSD1
and CL3 with alanine and determined the effects of these substitutions on MRP1 expression and transport activity. All singly substituted
MRP1-Pro mutants could be expressed in HeLa cells, except MRP1-P104A. The expressed mutants also transported LTC4 and E217hG, and
their Km (LTC4) values were similar to wild-type MRP1. Expression of the double mutant MRP1-P42/51Awas reduced by >80% although it
localized to the plasma membrane and transported organic anions. MRP1 expression was also reduced when the first transmembrane helix
(amino acids 37–54) was deleted. In contrast, the phenotypes of the multiply substituted CL3 mutants MRP1-P196/205/207/209A and
MRP1-P235/255A were comparable to wild-type MRP1. However, Pro255-substituted MRP1 mutants showed reduced immunoreactivity
with a monoclonal antibody (MAb) whose epitope is located in CL3. We conclude that certain prolines in MSD1 and CL3 play a role in the
expression and structure of MRP1.
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1. Introduction across biological membranes including sugars, aminoThe ATP-binding cassette (ABC) transporter proteins
comprise one of the largest known superfamilies of pro-
teins [1,2]. ABC proteins are found in bacteria, archaea,
and eukaryotes, and more than 500 have been sequenced
to date. These proteins are responsible for the ATP-
hydrolysis-driven transport of a wide variety of molecules0005-2736/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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peptides, proteins, and complex carbohydrates. Current
annotation of the human genome sequence indicates that
there are 48 human ABC genes and these have been
assigned to one of seven subfamilies, designated A
through G, based on the relative similarities of their
deduced amino acid sequences [3]. A number of these
proteins play a prominent role in essential physiological
processes, and mutations in several ABC genes are now
known to be the underlying cause of certain genetic
disorders. For example, conjugated hyperbilirubinemia
(Dubin–Johnson syndrome) is caused by mutations in
the ABCC2 gene encoding the canalicular multispecific
organic anion transporter cMOAT/MRP2 [4], and cystic
fibrosis is caused by mutations in the cystic fibrosis
transmembrane conductance regulator (CFTR; ABCC7)
gene that encodes an ATP-gated cAMP-regulated chloride
channel [5,6].
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ABC proteins are increasingly being implicated as important
determinants of drug efficacy and toxicity because of their
role in the absorption, disposition, and elimination of xeno-
biotics and their metabolites. Moreover, when overex-
pressed in tumor cells, some ABC proteins, most notably
the 170-kDa P-glycoprotein (gene symbol MDR1 or
ABCB1) and the 190-kDa multidrug resistance protein 1,
MRP1 (gene symbol ABCC1), can cause resistance to a
wide variety of clinically important chemotherapeutic
agents [7–11].
Almost all known ABC transporters are characterized by
a structure that includes at least one hydrophobic polytopic
membrane spanning domain (MSD) with up to six trans-
membrane (TM) segments, and one hydrophilic cytosolic
nucleotide binding domain (NBD) that contains three highly
conserved sequence motifs, viz., the Walker A and B motifs
and the so-called ‘active transport family’ signature [1,12].
In bacteria, these structural domains are usually encoded as
separate polypeptides which then associate with one another
to form an active transporter. Eukaryotic ABC transporters,
on the other hand, typically contain four domains config-
ured either as two alternating MSDs and NBDs encoded as a
single large polypeptide (e.g. CFTR and P-glycoprotein), or
as two independently encoded ‘half-molecules’ which asso-
ciate to form a functional dimer with both the NH2 and
COOH termini located in the cytoplasm.
Exceptions to this four domain structure include several
members of the ‘‘C’’ subfamily of ABC transporters. These
proteins, which include MRP1, contain a fifth domain,
MSD1, with five TM helices. This configuration places
the NH2 terminus of these proteins on the extracellular face
of the membrane [13–15]. Previous studies have shown that
portions of the first 280 amino acids of MRP1 encompass-
ing the NH2-terminal MSD1 (sometimes referred to as
MSDo) and the cytoplasmic loop (CL3 or Lo) connecting
it to the second MSD are important for transport activity in
insect and mammalian cell membranes [16–18]. For exam-
ple, we found that NH2-terminally truncated MRP1 poly-
peptides in which the first 66, 228, or 282 amino acids were
eliminated did not show detectable LTC4 transport activity
when expressed in insect cell membranes [16]. On the other
hand, Bakos et al. [17] demonstrated that the first 204 amino
acids of MRP1 can be removed without loss of LTC4 and
vinblastine transport activity. Thus, the precise function of
this region in MRP1 and related ABCC proteins is not yet
fully understood.
Proline residues located in the MSDs and cytosolic
domains of transport proteins, including P-glycoprotein
and CFTR [19–21], have frequently been shown to play
an important role in ensuring proper protein folding and
function in mammalian cells. To investigate whether any of
the Pro residues within the first 280 amino acids of MRP1
play a similar role in this ABC transporter, we have replaced
them with Ala residues, singly, and in some cases, in
combination, by site-directed mutagenesis. The effects ofthese mutations on MRP1 expression levels, membrane
localization, and organic anion transport activity were then
determined using HeLa cells stably transfected with the
mutant proteins.2. Materials and methods
2.1. Materials
[6,7-3H]E217hG (55 Ci mmol
 1) was purchased from
NEN Life Science Research Products (Boston, MA) and
[14,15 (n)-3H]LTC4 (115.3 Ci mmol
 1) was from Amer-
sham Pharmacia Biotech (Buckinghamshire, UK). LTC4
was purchased from CalBiochem (La Jolla, CA) and
nucleotides and E217hG were purchased from Sigma
Chemical Co. (St. Louis, MO).
2.2. Site-directed mutagenesis and vector construction
The expression vector pcDNA3.1( )-MRP1K contain-
ing wild-type MRP1 with an optimized Kozak sequence at
the ATG codon has been described previously [22]. The
template for mutagenesis was prepared by cloning the XbaI/
BamHI fragment from pcDNA3.1( )-MRP1K (containing
nucleotides  24 to + 840 of the MRP1 sequence encoding
the first 280 amino acids of the protein) into pGEM7-3Z
(Promega, Madison, WI). Mutagenesis was performed using
the Transformerk site-directed mutagenesis kit (Clontech
Laboratories Inc., Palo Alto, CA) according to the manu-
facturer’s instructions.
For the single substitutions of Pro with Ala in MSD1,
the following sense mutagenic primers were used (substi-
tuted nucleotides are underlined): MRP1-P42A (5V-C GTG
TGG GTG GCT TGT TTT TAC CTC TGG-3V), MRP1-
P51A (5V-G GCC TGT TTC GCC TTC TAC TTC C-3V),
MRP1-P69A (5V-CAG ATG ACA GCT CTC AAC-3V),
MRP1-P104A (5V-C ATA TTC CTG GCC GCA GTG
TTT CTG G-3V), MRP1-P110A (5V-GT TTC TGG TCA
GCG CAA CTC TCT TGG-3V). For substitution of Pro
residues in the CL3 loop connecting MSD1 to MSD2, the
mutagenic primers were: MRP1-P196A (5V-CA GAT CGC
TCA GCC CTG TTC TC-3V), MRP1-P205A (5V-C ATC
CAC GAC GCT AAT CCC TG-3V), MRP1-P207A (5V-C
GAC CCT AAT GCC TGC CCA GAG-3V), MRP1-P209A
(5V-CTA ATC CCT GCG CAG AGT CCA G-3V), MRP1-
P235A (5V-C TAC CGC CAG GCC CTG GAG GG-3V),
MRP1-P255A (5V-CG GAA CAA GTC GTG GCT GTT
TTG G-3V), MRP1-P272A (5V-CT AGG AAG CAG GCG
GTG AAG G-3V).
A selected number of multiply substituted MRP1 con-
structs and a construct eliminating amino acids 37–54
corresponding to the predicted first TM segment of MRP1
were also created using the same mutagenesis protocol as
above with the following primers: MRP1-P42/51A (5V-C
GTG TGG GTG GCT TGT TTT TAC CTC TGG GCC
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(5V-GGC ATA TTC CTG GCC GCA GTG TTT CTG GTC
AGC GCA ACT CTC TTG GGC-3V); MRP1-P205/207/
209A (5V-C ATC CAC GAC GCT AAT GCC TGC GCA
GAG TCC AG-3V), and MRP1-Del37-54 (5V-GCT TTC
AGA ACA CGC TCTATC TCT CCC G-3V). The quadruple
MRP1-P196/205/207/209A construct was generated by in-
troducing the P205/207/209A mutations into the MRP1-
P196A construct. MRP1-P235/255A was generated by in-
troducing P255A into the MRP1-P235A construct. After
confirming all mutations by sequencing or diagnostic re-
striction enzyme digests, the 0.87 kb XbaI/BamHI fragment
was subcloned back into pcDNA3.1( )-MRP1K and the
integrity of the inserts and the cloning boundaries in the full-
length constructs was verified by DNA sequencing.
Construction of the pcDNA3.1( )-MRP1K-GFP vec-
tor has been described previously [22,23]. Selected mu-
tant MRP1-GFP fusion proteins were generated by
replacing the XbaI/BamHI fragment in pcDNA3.1( )-
MRP1K-GFP with the comparable fragment containing
the desired mutation from the vectors described above
and the integrity of the subcloning was again confirmed
by DNA sequencing.
2.3. Transfections of MRP1 expression vectors
To obtain stably transfected cell lines, wild-type and
mutant MRP1 pcDNA3.1( ) expression vectors or the
empty vector were transfected into HeLa cells using
FuGENE6 (Roche Biochemicals, Laval, PQ, Canada) as
described [22]. Briefly, approximately 1.5–2 106 cells
were seeded in each well of a six-well plate and 24
h later, 1-Ag DNA mixed with FuGENE6 according to
the manufacturer’s protocol was added. After 48 h, the
cells were subcultured 1:12 and the medium replaced
with fresh medium containing G418 (geneticin) (1000 Ag
ml 1). After approximately 2 weeks, cell colonies were
individually removed using cloning cylinders and subcul-
tured in 600 Ag ml 1 G418. Levels of MRP1 protein in
G418-resistant cell populations were then determined by
dot blotting and/or immunoblotting as described below.
The proportion of cells expressing the mutant MRP1
proteins was determined by flow cytometry using the
MRP1-specific MAb QCRL-3 which recognizes a con-
formation-dependent epitope in the first NBD of MRP1
as described previously [22,24,25]. Several HeLa cell
populations containing the greatest number of MRP1
positive cells were then cloned by limiting dilution and
expanded to obtain clonal cell lines with >90% of the
cells expressing wild-type or mutant MRP1. For some
mutants, transient transfections were carried out with
SV40-transformed human embryonic kidney cells
(HEK293T). Briefly, 1.5–2 106 cells were seeded in
each well of a six-well plate and, after 24 h, were
exposed to 1 Ag of DNA with FuGENE6. Cells were
harvested 48–60 h later [22].2.4. Determination of MRP1 protein levels in transfected
cells
The levels of wild-type and mutant MRP1 proteins
were determined by immunoblot and/or dot blot analysis
of membrane protein fractions from transfected cells
essentially as described [25]. The antibodies used were
the murine MAb QCRL-1, which recognizes a linear
heptapeptide epitope comprised of amino acids 918–924
in the linker region of MRP1 [24,26], and the rat MAb
MRPr1, which recognizes a linear epitope in the cytosolic
region of MRP1 connecting MSD1 to MSD2 (amino
acids 238–247) [27]. Dot blots were prepared on Immo-
bilon P membrane in a 96-well manifold as described
previously [25]. For immunoblotting, proteins were re-
solved on a 6% or 7% polyacrylamide gel and electro-
transferred to a nylon membrane. MAb QCRL-1 and
MAb MRPr1 binding to the dot blots and immunoblots
was detected with horseradish peroxidase-conjugated goat
anti-mouse and goat anti-rat IgG (H +L) (Pierce, Edmon-
ton, Alberta, Canada), respectively, followed by enhanced
chemiluminescence detection (NEN Life Science Re-
search Products). Relative levels of MRP1 expression
were estimated by densitometric analysis using a Chem-
iImagerJ 4000 (Alpha Innotech, San Leandro, CA). In
some cases, the glycosylation state of selected Pro-MRP1
mutants was determined by subjecting membrane proteins
to PNGaseF treatment as before [25] and then immuno-
blotted as described above.
2.5. Localization of MRP1 by confocal microscopy
The localization of the MRP1 proteins in the trans-
fected HeLa cells was determined by indirect immuno-
fluorescence with MAb QCRL-3. Briefly, cells were
seeded at 1.5 106 cells per well in six-well plates on
coverslips coated with 0.1% gelatin in 2 ml of serum-
containing medium. The following day, the coverslips
were washed once with PBS and the cells fixed with
4% paraformaldehyde for 10 min at room temperature.
After washing twice with PBS, the cells were permeabi-
lized by incubation in 0.2% Triton X-100 in PBS for 5
min. The coverslips were then washed 3 5 min in
blocking solution (0.1% Triton X-100/1% BSA in
PBS). MAb QCRL-3 [diluted 1:2500 in blocking solution
with 10 Ag ml 1 RNaseA (Roche Molecular Biochem-
icals)] was added and the cells incubated with gentle
shaking for 60 min at room temperature. After washing
with blocking solution, 500-Al Alexa Fluor 488 conju-
gated goat anti-mouse IgG (H + L) (FabV)2 fragment
(Molecular Probes, Eugene, OR) (diluted 1:1000 in
blocking solution with 10 Ag ml 1 RNaseA) was added
and the coverslips incubated 30 min in the dark. The
coverslips were washed again and cell nuclei stained by
incubation in 1-ml propidium iodide (2 Ag ml 1 in PBS)
for 45 min in the dark. Finally, the coverslip was placed
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(Molecular Probes) and cells examined and photographed
using a Meridien InSight confocal microscope equipped
with an air-cooled argon laser. Fluorescent signals were
collected with a 530/30 nm bandpass filter and propidium
iodide signals were collected with a 620/40 nm bandpass
filter. Images obtained with 488-nm excitation were
pseudo-colored using Maxim DL software.
Confocal microscopy was also used to examine the
cellular localization of several GFP-tagged MRP1 con-
structs expressed in transiently transfected cells. Briefly,
HEK293T cells were seeded at 3 105 cells per well in a
six-well plate on gelatin-coated coverslips and, 24 h later,
transfected with the MRP1-GFP cDNA constructs as de-
scribed above for the stably transfected HeLa cells. Forty
eight hours later, the coverslips were washed and the cells
fixed with 4% paraformaldehyde for 10 min and permeabi-
lized by adding 0.2% Triton X-100 in PBS for 5 min. The
coverslips were then incubated in RNaseA followed by
nuclear staining with propidium iodide and viewed as
before. Propidium iodide signals were collected with a
620/40 nm bandpass filter and GFP signals were collected
with a 530/30 nm bandpass filter.
2.6. MRP1-mediated LTC4 and E217bG transport in
inside-out membrane vesicles
Membrane vesicles were prepared from transfected cells
and used to measure ATP-dependent [3H]LTC4 and
[3H]E217hG transport according to a rapid filtration tech-
nique described previously [28]. Briefly, [3H]LTC4 transport
assays were performed at 23 jC in a 50-Al reaction con-
taining 50 nM substrate (40 nCi per reaction), 4 mM ATP,
10 mM MgCl2, 10 mM creatine phosphate, 100 Ag ml 1
creatine kinase, and 2–4 Ag of membrane vesicle protein.
Uptake was stopped at selected times by rapid dilution in
ice-cold buffer, and then the reaction was filtered through
glass fiber (Type A/E) filters presoaked in transport buffer.
Radioactivity was quantitated by liquid scintillation count-
ing and all data were corrected for the amount of [3H]LTC4
that remained bound to the filter, which was usually < 10%
of the total radioactivity. Transport in the presence of AMP
was subtracted from transport in the presence of ATP to
determine ATP-dependent uptake of [3H]-labelled substrate.
After preliminary time courses, kinetic parameters (Km and
Vmax) were determined by measuring initial rates of
[3H]LTC4 uptake into membrane vesicles for 45 s at several
substrate concentrations. Eadie–Hofstee plots were gener-
ated from initial rate measurements using GraphPad Prism7
software (San Diego, CA).
[3H]E217hG uptake was also measured in a similar
fashion except that membrane vesicles were incubated at
37 jC for a single time point (120 sec) in a total reaction
volume of 50 Al at an initial E217hG concentration of 400
nM (40 nCi per reaction). The remaining components were
as described above for LTC4 transport. All transport assayswere carried out in triplicate and were repeated at least
once.3. Results
3.1. Most MRP1-Pro mutants can be stably expressed in
transfected HeLa cells
Pro residues in MRP1 MSD1 (at positions 42, 51, 69,
104, and 110) and the cytosolic loop (CL3) connecting
MSD1 to MSD2 (at positions 196, 205, 207, 209, 235, 255
and 272) (Fig. 1) were replaced singly, and in some cases, in
combination, with Ala. The resulting mutant MRP1 con-
structs were transfected into HeLa cells and clonal HeLa cell
lines established. Despite multiple attempts, stable HeLa
cell lines expressing MRP1-P104A and MRP1-P104/110A
could not be established.
Immunoblots of membrane vesicles prepared from the cell
lines expressing MSD1 MRP1 mutants containing single
(P42A, P51A, P69A and P110A) and double (P42/51A)
Pro substitutions detected with MAb QCRL-1 are shown in
Fig. 2A. The relative expression levels of the different
mutants ranged from < 20% to approximately 150% that of
wild-type MRP1. The double TM1 mutant, MRP1-P42/51A,
was consistently expressed at very low levels ( < 20% wild-
type MRP1) in multiple independent transfections, suggest-
ing that biogenesis of this mutant MRP1 was impaired or that
the mutant protein was not very stable. Treatment of mem-
brane proteins prepared from cells expressing this mutant
MRP1 with PNGaseF showed that the small amount of
MRP1 made was fully glycosylated (not shown).
The seven single (P196A, P205A, P207A, P209A,
P235A, P255A, and P272A) and two multiply substituted
CL3 mutants (P196/205/207/209A and P235/255A) could
also be stably expressed in HeLa cells. The relative expres-
sion levels of these mutants as determined by immunoblot-
ting with MAb QCRL-1 ranged from approximately 50% to
160% that of wild-type MRP1 (Fig. 2B).
3.2. MRP1 lacking TM1 (amino acids 37–54) cannot be
expressed in HeLa cells and is poorly expressed in
HEK293T cell
Because the MRP1-P42/51A mutant was so poorly
expressed, we further explored the contribution of TM1
to the expression and activity of MRP1 by creating a
mutant which did not contain this transmembrane segment
(MRP1-Del37-54). Stable HeLa cell lines expressing sig-
nificant levels of this deletion mutant could not be estab-
lished. However, the low level of MRP1-Del37-54
expressed in transiently transfected HEK293T cells migrat-
ed as a tight band with a significantly faster electrophoretic
mobility than the diffuse band observed for wild-type
MRP1, indicating that glycosylation of the MRP1-Del37-
54 mutant was impaired (Fig. 3).
Fig. 1. Schematic diagram of a predicted secondary structure of MRP1 showing the positions of the Pro residues in MSD1 and CL3 replaced with Ala residues
in this study. The MAb MRPr1 epitope is located between amino acids 238 and 247 in CL3 and the MAb QCRL-1 epitope between amino acids 918 and 924
are indicated [26,27].
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MRP1-Del37-54 is impaired
To examine the cellular localization of the different
MRP1-Pro mutant proteins, the transfected HeLa cells were
grown to confluence and stained with the MRP1-specificFig. 2. Immunoblot analysis of mutant MRP1 molecules containing MSD1
and CL3 Pro substitutions expressed in transfected HeLa cells. Relative
levels of wild-type and MRP1-Pro mutant proteins in HeLa cell membranes
were determined by immunoblotting with the MRP1-specific murine MAb
QCRL-1 as described in Materials and methods. (A) Immunoblot of MSD1
(aa 1–195) MRP1-Pro mutant proteins. (B) Immunoblot of CL3 (aa 196–
281) MRP1-Pro mutant proteins.MAb QCRL-3, and then viewed by confocal microscopy
[22,24]. Representative confocal micrographs of wild-type
and MSD1 MRP1-Pro mutant proteins are shown in Fig.
4A. Wild-type MRP1 localized strongly to the plasma
membrane as expected (Fig. 4A, first panel). Similarly, the
singly substituted MRP1-Pro mutants P42A, P51A, P69A,
and P110A localized strongly to the plasma membrane,
similar to wild-type MRP1 (MRP1-P42A and MRP1-
P51A shown in Fig. 4A, middle two panels). In marked
contrast, cells transfected with the double mutant MRP1-
P42/51A showed very weak plasma membrane staining andFig. 3. Immunoblot analysis of TM1 deletion mutant MRP1-Del37-54.
Expression of wild-type MRP1 and MRP1-Del37-54 in membranes
prepared from transiently transfected HEK293T cells was determined by
immunoblotting with the MRP1-specific murine MAb QCRL-1 as
described in Materials and methods.
Fig. 4. Confocal laser scanning micrographs of cells expressing wild-type MRP1, TM1 and CL3 MRP1-Pro mutant proteins. (A) HeLa cells expressing wild-
type MRP1, MRP1-P42A, MRP1-P51A, and MRP1-P42/51Awere seeded at 1.5 106 cells per well and processed 24 h later for indirect immunofluorescence
and confocal microscopy. MRP1 proteins were detected using MAb QCRL-3, visualized with Alexa 488-tagged secondary antibody, and are shown in green.
Nuclei were stained with propidium iodide and are shown in red. No green fluorescence was detected in HeLa cells transfected with pcDNA3.1( ) vector
alone (not shown). (B) HEK293T cells were seeded at 3 105 cells per well and 24 h later, transfected with cDNAs encoding GFP-tagged wild-type MRP1,
MRP1-P42/51A, and TM1 deletion mutant, MRP1-Del37-54. Cells were viewed by confocal microscopy 48 h later. GFP-tagged MRP1 proteins are shown in
green; nuclei were stained with propidium iodide and are shown in red. (C) HeLa cells stably expressing wild-type MRP1, MRP1-P235A, MRP1-P255A,
MRP1-P235/255A, and MRP1-P196/205/207/209A were cultured and processed for immunofluorescence and confocal microscopy as described in panel A.
The horizontal white scale bar in the photographs represents 20 Am.
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is evident by the densely fluorescent spots observed (Fig.
4A, fourth panel).
To confirm that the plasma membrane trafficking of the
MRP1-P42/51A mutant was impaired, a COOH-terminally
GFP-tagged derivative of P42/51A was created and tran-
siently expressed in HEK293T cells. When cells were
viewed under the confocal microscope, GFP-tagged wild-
type MRP1 localized to the plasma membrane as expected
(Fig. 4B, left panel). On the other hand, MRP1-P42/51A-
GFP (Fig. 4B, middle panel) showed significant intracellular
fluorescence similar to the indirect immunofluorescent
staining observed with MAb QCRL-3 in the stably trans-
fected HeLa cells (Fig. 4A, fourth panel). The GFP-tagged
mutant showed more plasma membrane localization in the
HEK cells than in the stable HeLa cell transfectants, likely
due to the higher levels of expression achieved in the
transiently transfected HEK cells. Taken together, these
results indicate that Ala substitution of the two Pro residues
in TM1 at the same time alters MRP1 such that both its
expression and plasma membrane localization are impaired.HeLa cells transfected with the TM1 deletion mutant
MRP1-Del37-54 were also examined by indirect immuno-
fluorescence and showed that in the few cells expressing
this mutant, its plasma membrane trafficking was severely
disrupted (not shown). Similarly, when a GFP-tagged
construct (MRP1-Del37-54-GFP) was transiently expressed
in HEK293T cells and examined by confocal microscopy,
very little of the protein was observed in the plasma
membrane despite the fact that the N-glycosylation sites
at positions 19 and 23 were still present (Fig. 4B, right
panel).
3.4. Mutation of Pro255 alters the conformation of CL3
For initial immunoblotting experiments, the well-charac-
terized human MRP1-specific MAb QCRL-1, which detects
an epitope in the linker region between NBD1 and MSD3,
was used. Subsequently, membranes from HeLa cells
expressing the MRP1 mutants with Ala substitutions of
P235, P255, and P272 were also immunoblotted with
MAb MRPr1 since the epitope of this MAb is located in
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P255A, P235/255A, and P272A MRP1 mutants probed
with MAb QCRL-1 and MAb MRPr1 indicated that detec-
tion of the P255A and P235/P255A mutant MRP1 proteins
relative to wild-type MRP1 by MAb MRPr1 was lower than
that by MAb QCRL-1 (not shown). To quantitate these
differences in immunoreactivity more accurately, dot blot
analyses of serial dilutions of membrane vesicles were
carried out with these two MRP1-specific MAbs (Fig. 5).Fig. 5. Dot blot analyses of MRP1 expression in membranes from HeLa cells expr
Serial dilutions of membrane proteins (0, 0.25, 0.5, 1, 2, and 4 Ag) were spotted i
MRP1-P235/255A mutants probed with (A) MAb QCRL-1 and (B) MAb MRP
QCRL-1 and (D) MAb MRPr1. Graphic representations of densitometric analyses
MRP1-P235A (E); MRP1-P235/255A (z). (C and D) Wild-type MRP1 (n); MWhen MRP1-P235A was detected with MAb QCRL-1,
the signal intensity was approximately 1.8-fold higher than
that for wild-type MRP1, while the signal intensity for
MRP1-P235/P255A was approximately 2.3-fold higher
(Fig. 5A). When MRP1-P235A was detected with MAb
MRPr1, the signal intensity was also higher than that of
wild-type MRP1 (approximately 1.4-fold) but the signal
intensity for P235/255A was less than that of wild-type
MRP1 (approximately 75%) (Fig. 5B). Thus, MRP1-P235Aessing CL3 mutants MRP1-P235A, MRP1-P255A, and MRP1-P235/255A.
n duplicate onto nylon membranes as described [25,27]. MRP1-P235A and
r1. MRP1-P255A and MRP1-P235/255A mutants probed with (C) MAb
are shown beneath each of the dot blots. (A and B) Wild-type MRP1 (n);
RP1-P255A (E); MRP1-P235/255A (z).
Table 1
Kinetic parameters of [3H]LTC4 uptake by membrane vesicles prepared
from transfected HeLa cells expressing MRP1-Pro mutants
Transfected
cell line
Km
(nM)
Vmax
(pmol min 1 mg 1)
Normalized
Vmax
MSD1 mutants
WT-MRP1 128 80 80
P42A 139 35 41
P51A 109 55 50
P42/51A 103 15 48
P69A 142 46 42
P110A 150 73 124
CL3 mutants
WT-MRP1 88 57 57
P196A 143 25 52
P205A 63 14 88
P207A 81 75 110
P209A 112 121 85
P196/205/207/209A 90 87 94
P235A 91 45 30
P255A 99 110 67
P235/255A 97 81 35
P272A 80 59 109
The kinetic parameters of [3H]LTC4 uptake were determined by regression
analysis of the Eadie–Hofstee transformed data. The normalized Vmax
values were obtained by correcting determined Vmax values for differences
in MRP1 expression levels as determined by immunoblot analysis. Results
shown are means of triplicate determinations within a single experiment.
Similar results were obtained in a second independent experiment.
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antibodies whereas the double mutant MRP1-P235/255A
was not.
We next compared the immunoreactivity of the double
mutant MRP1-P235/255A and the single mutant MRP1-
P255A. When detected with MAb QCRL-1, the signal
intensity for MRP1-P255A was approximately 1.3-fold
higher than that for wild-type MRP1 (Fig. 5C). In contrast,
the signal intensity of MRP1-P255A detected with MAb
MRPr1 was only 50% that of wild-type MRP1 detected with
the same MAb (Fig. 5D). Overall, these findings suggest
that substitution of Pro255 with Ala might introduce a
change in the structure of this region of MRP1 such that
the MRPr1 epitope is less accessible to the MAb.
3.5. Plasma membrane localization of CL3 MRP1-Pro
mutants is unchanged in transfected HeLa cells
The changes in immunoreactivity of the MRP1-P255A
and MRP1-P235/255A mutant proteins suggested that the
Pro255 to Ala substitution introduced a conformation change
in CL3. To determine whether this change might also affect
plasma membrane trafficking of MRP1-P255A, transfected
HeLa cells expressing this mutant as well as the MRP1-
P235A and MRP1-P235/255A mutants were examined by
confocal microscopy as before. Like wild-type MRP1,
MRP1-P255A as well as MRP1-P235A and MRP1-P235/
255A localized mostly to the plasma membrane of confluent
HeLa cells (Fig. 4C). Thus, despite the apparent change in
conformation of MRP1 proteins containing the Pro255-Ala
substitution, their expression at the plasma membrane
remained unchanged. Plasma membrane staining was also
observed in cells expressing the quadruple MRP1-P196/
205/207/209A mutant.
3.6. LTC4 and E217bG transport activity of MSD1 and CL3
MRP1-Pro mutants
To determine whether any of the Pro substitutions affect-
ed organic anion transport by MRP1, the activity of the
various Pro mutants was examined using membrane vesicles
prepared from the transfected HeLa cell lines and LTC4 as
substrate. The kinetic parameters of LTC4 transport obtained
for the wild-type and MRP1-Pro mutants are summarized in
Table 1. Two sets of experiments are shown because it was
technically not feasible to measure kinetic parameters of all
mutants in a single experiment. The differences in the Km
values obtained for wild-type MRP1 in the two sets of
experiments are within the range reported in the literature.
Vmax values that were normalized to take into account
differences in expression levels of the various MRP1
mutants relative to the wild-type protein are also shown.
In the first set of experiments, the Km (LTC4) values for
the four single MSD1 mutant proteins (range 103–150 nM)
were found to be comparable to that of wild-type MRP1
(128 nM). When normalized for relative MRP1 expressionlevels, the Vmax values of these mutants ranged from 41 to
124 pmol mg protein 1 min 1 versus 80 pmol mg
protein 1 min 1 for wild-type MRP1. Thus, all of the
MSD1 Pro mutants retained the ability to transport LTC4
with TM1 mutants P42A, P51A, and P69A showing an
approximately 30–50% decrease in relative LTC4 transport
efficiency, while P110A (TM3) showed an increase of
approximately 50%. Expression levels of the double P42/
51ATM1 mutant were so low that reliable estimates of Vmax
for LTC4 transport could not be obtained; the Km was
estimated to be similar to wild-type MRP1.
In the second set of experiments, the Km (LTC4) values for
the seven singly substituted CL3 mutant MRP1 proteins were
determined to range from 63 to 143 nM compared to 88 nM
for wild-type MRP1. The normalized Vmax values for these
mutants ranged from 30 to 110 pmol mg protein 1 min 1
compared to 57 pmol mg protein 1 min 1 for wild-type
MRP1. Thus, the level of LTC4 transport by these mutants
ranged from approximately 0.5- to 2-fold that of wild-type
MRP1. The transport kinetics for the multiply substituted
MRP1 CL3 mutants were also determined. MRP1-P196/205/
207/209A displayed LTC4 transport activity comparable to
that of wild-type MRP1 whereas transport by the MRP1-
P235/255A mutant was reduced by approximately 25%.
To determine whether E217hG uptake was affected by
Ala substitution of the Pro residues in MSD1 and CL3,
transport of this substrate was also measured in membrane
vesicles enriched for the various mutant proteins at a single
time point. Results were expressed relative to wild-type
Fig. 6. [3H]E217hG uptake by membrane vesicles prepared from HeLa cells
expressing MRP1-Pro mutant proteins. The levels of [3H]E217hG uptake
are expressed relative to wild-type MRP1 transport activity after normal-
ization of the data to take into account differences in MRP1 expression of
the various mutants. Bars represent the means of results obtained in two
independent experiments.
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differences in relative MRP1 expression and are shown in
Fig. 6. E217hG uptake levels by the four single Pro MSD1
mutants P42A, P51A, P69A, and P110A were 48%, 43%,
95%, and 95% those of wild-type MRP1, respectively.
E217hG uptake by the double P42/51A TM1 mutant was
approximately 25% that of wild-type MRP1 although,
again, expression levels of this mutant were so low that
this estimate may not be reliable.
All seven single CL3 mutants transported E217hG,
with levels of uptake ranging from approximately 0.5- to
2-fold that of wild-type MRP1. E217hG uptake by the
MRP1-P196/205/207/209A quadruple mutant was compa-
rable to that of wild-type MRP1 as was uptake by the
double MRP1-P235/255A mutant. Thus, although there
was some variability, all MRP1-Pro mutants retained the
ability to transport this glucuronide conjugated substrate
as well as LTC4.4. Discussion
In this study we have characterized the structural and
functional consequences of substituting an Ala residue for
each of the five Pro residues in MSD1 and seven Pro
residues in CL3 of MRP1. Eleven of the twelve single
MRP1-Pro mutants could be stably expressed in HeLa cells;
the exception was a mutant containing an Ala in place of
Pro104. The double MRP1-P104/110A protein was also not
detected in stable transfectants. Exactly why these MRP1-
Pro104 mutant proteins were not expressed is unclear;
however, Pro104 is predicted to be located in the relatively
short extracellular loop between TM2 and TM3 and thus
may be critical for ensuring the proper insertion of TM3 inthe membrane during the biosynthesis and folding of MRP1,
at least in HeLa cells [29,30]. Misfolding of MRP1 could
lead to its rapid degradation and thus explain why mutant
MRP1 molecules containing Pro104 substitutions could not
be detected.
It has previously been noted that Pro residues are often
found in the TM segments of ion channels and transporters
but not in the TMs of proteins that have no transport
function [19]. Presumably because of proline’s ability to
create a kink in an a-helical structure, this amino acid has
frequently been shown to play an important structural and/or
functional role when located in the MSDs of certain
transport proteins and ion channels including the ABC
proteins CFTR and P-glycoprotein [20,21,31,32]. Pro resi-
dues present at a given position i in a-helices (as is
predicted for Pro42, Pro51, and Pro110) cannot form hydro-
gen bonds to the carbonyl oxygens of amino acids at
positions i-3 and i-4. In this way, proline-containing motifs
can distort the helix and may in some cases form so-called
‘molecular hinges’ [33,34]. Such hinges may be critical for
the conformational changes in MSDs required to transduce
signals across membranes. However, in the present study,
we have shown that single Ala substitutions of the TM
residues Pro42, Pro51, and Pro110 do not cause any major
alterations in MRP1 expression nor its plasma membrane
localization or organic anion transport activity. This sug-
gests that none of these residues contribute to a functionally
important molecular hinge in MRP1. Whether or not Pro-
induced helix distortions or flexibility in other MSDs of
MRP1 might play a role in the conformational changes that
accompany substrate binding and translocation (and/or
nucleotide binding and hydrolysis) is not yet known.
In contrast to the single Pro mutants, expression levels of
the double TM1 mutant MRP1-P42/51A were reduced by
more than 80%. The exact role of TM1 in the assembly of
functional MRP1 at the plasma membrane is not fully
understood. Zhang [29] found that TM1 did not have
enough activity to initiate membrane translocation in an in
vitro translation reporter system and that TM2 was required.
In addition, we previously demonstrated that a mutant
lacking the first 66 amino acids of MRP1 including TM1
(MRP167–1531) could be expressed in insect cell membranes
but could not transport LTC4 [16]. On the other hand, we
have also shown that single substitutions of several other
TM1 residues (Trp40, Cys43, Tyr45, Trp47, Cys49, Tyr53) did
not significantly affect MRP1 expression and caused no, or
only substrate-selective, changes in transport activity
[23,35] (C.J. Oleschuk, R.G. Deeley and S.P.C. Cole,
unpublished work). Similarly, the expression of the single
Pro42 and Pro51 mutants appeared comparable to wild-type
MRP1 and transport activity was only moderately reduced.
Thus, a substantial number of single amino acid substitu-
tions can be made in TM1 without a major loss in protein
expression levels and transport activity. This raises the
possibility that the lack of LTC4 transport activity observed
for the MRP167–1531 truncation mutant might be attributed
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the protein that precede TM1. Consistent with this idea are
the recent findings of Yang et al. [36] which showed that
replacement of Cys7 with Ala caused an almost complete
loss of LTC4 transport activity and a change in conformation
of the NH2 terminus although expression levels and plasma
membrane localization of this mutant MRP1 were not
diminished compared to wild-type MRP1.
The presence of Pro42 and Pro51 in wild-type MRP1
introduces a significant distortion into the backbone of TM1
which completely disappears when these two residues are
both replaced with Ala as in the MRP1-P42/51A mutant
(Fig. 7). This straightening of the TM1 a-helical axis would
be expected to change the angle between the plane of the
helix and the plane of the side chains of the aromatic amino
acids found there (Trp40, Tyr45, Trp47, Phe50, Phe52, Tyr53,
and Phe54). This change in angle could lead to a disruption
of the packing of TM1 with other TM helices of MRP1
which in turn could destabilize the protein or impair its
folding, leading to enhanced protein degradation. The small
amount of MRP1-P42/51A expressed in the transfected
HeLa cells appears fully glycosylated and a portion of it
is present in the plasma membrane of HEK cells, indicating
that processing was not grossly affected by the mutations.
Furthermore, when corrected for relative MRP1 expression
levels, organic anion transport activity seemed intact or only
modestly altered. Thus, the double Pro substitution in TM1
appears to destabilize MRP1 rather than affect its ability to
transport organic anions. MRP1 protein expression was also
reduced when the entire TM1 helix (aa 37–54) was deleted,
but in contrast to the P42/51A mutant, this deletion mutant
MRP1 molecule was not glycosylated. Thus, both our
previous and present observations [23,35] indicate that
although many single-amino-acid substitutions in TM1
can be tolerated without substantial loss of transport activityFig. 7. Models illustrating the predicted differences in the a-helical axis of
TM1 in wild-type MRP1 and MRP1-Pro mutants P42A, P51A, and P42/
51A. Models were generated using Sybyl (Tripos Inc., St. Louis, MO) and
images were prepared using Web Lab viewer Pro42 (Accelrys Inc., San
Diego, CA). N, NH2 terminus; C, COOH terminus.or plasma membrane localization, TM1 nevertheless appears
to play some role in facilitating the stable expression of
MRP1 in mammalian cell membranes.
Previous studies have shown that the cytoplasmic linker
CL3 connecting MSD1 to MSD2 (i.e. aa 204–281) is
important for transport activity as well as for the correct
routing of MRP1 to the basolateral plasma membrane of
polarized epithelial cells [16–18]. Indeed, this region may
be considered a distinct protein domain within MRP1 since
at least portions of it can form specific associations with the
core four-domain region of the protein [18]. When Ala
residues were substituted individually for the seven Pro
residues in CL3, the mutant proteins were expressed at
levels comparable to those of wild-type MRP1 in most
cases. Similarly, all of the single CL3 MRP1-Pro mutants
trafficked appropriately to the plasma membrane and
exhibited significant levels of organic anion transport activ-
ity. Four of the seven CL3 Pro residues (Pro196, Pro205,
Pro207, Pro209) are located in a cluster at the beginning of the
loop, which might be expected to impose some constraints
on the structure of this region. Somewhat surprisingly,
however, when all four Pro residues were simultaneously
replaced with Ala, the properties of the mutant protein
(MRP1-P196/205/207/209A) were similar to those of
wild-type MRP1. Previously, Bakos et al. [18] demonstrated
that deletion of amino acids 223–232, which are predicted
to be within an amphipathic helix in CL3, eliminated MRP1
transport activity but not glycosylation or plasma membrane
routing. The four clustered Pro residues mutated in the
present study are located NH2-proximal to this helical
domain which may account for the absence of any major
phenotypic changes observed in the MRP1-P196/205/207/
209A mutant. Nevertheless, three of them are located very
close to the NH2 terminus of the minimal region of CL3 that
has been defined thus far to be necessary for LTC4 binding
and transport activity (amino acids 204–281) [17,37].
Interestingly, we have recently shown that Ala- and Ser-
substituted MRP1-Cys208 mutants also display phenotypes
similar to those of the wild-type protein [35].
Two of the more COOH-proximal CL3 Pro residues
(Pro235 and Pro255) are located near the linear epitope
recognized by the MRP1-specific MAb MRPr1 [27]. Con-
sequently, we wondered whether structural changes caused
by substitutions of these two Pro residues, alone or in
combination, might be detected as a change in reactivity
with this MAb. Indeed, substitution of Pro255 with Ala
caused a significant decrease in MRP1 reactivity with
MAb MRPr1 but not MAb QCRL-1, presumably reflecting
some conformational change in this region of the protein.
Nevertheless, neither the P255A mutant nor the P235/255A
double mutant showed major changes in plasma membrane
localization or organic anion transport. The change in MAb
MRPr1 reactivity caused by the P255A substitution was
unexpected. The Pro255 residue lies COOH-proximal to the
peptide sequence recognized by the MAb MRPr1 and,
furthermore, the epitope is linear and its detection would
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conditions of immunoblotting [27,38]. However, linear
epitopes are sometimes known to require some local struc-
tural distortion or involve closely spaced but non-contigu-
ous amino acids such as those found on one face of an
amphipathic a-helix [39]. Our data suggest that this may be
the case for MAb MRPr1 [18] and thus its description as a
linear epitope may not be completely accurate.
In conclusion, our studies show that Pro residues in
certain regions of the NH2-terminal MSD of MRP1 and
the cytoplasmic loop connecting it to the rest of the
molecule can play a role in the expression and structure of
this five domain ABC transporter protein. We have demon-
strated that the Pro42 and Pro51 residues in TM1 and
possibly the Pro104 residue in the extracellular loop con-
necting TM2 to TM3 are important for stable expression of
MRP1 in mammalian cell plasma membranes. In addition,
we have shown that certain structural changes in at least two
different regions of CL3 can be accommodated without loss
of transport activity or plasma membrane localization.
Finally, our finding that a mutant MRP1 molecule can show
a MAb-selective change in immunoreactivity could be
relevant to clinical studies of MRP1 expression and supports
the principle that expression levels of MRP-related proteins
should be verified with more than one antibody as has been
recommended previously for detection of P-glycoprotein
and other drug resistance markers [40].Acknowledgements
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